vs
COLONY BANKCORP INC（CBAN）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
COLONY BANKCORP INC的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.1倍（$39.9M vs $35.5M），COLONY BANKCORP INC净利率更高（20.6% vs -304.2%，领先324.8%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 19.6%）
Colony Bankcorp Inc是总部位于美国的银行控股公司，旗下运营Colony Bank，主要面向佐治亚州的个人消费者与中小企业，提供储蓄账户、贷款、抵押及财富管理等全方位个人及商业金融服务。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CBAN vs RXRX — 直观对比
营收规模更大
CBAN
是对方的1.1倍
$35.5M
净利率更高
CBAN
高出324.8%
-304.2%
两年增速更快
RXRX
近两年复合增速
19.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.9M | $35.5M |
| 净利润 | $8.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 20.6% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | 24.1% | 39.6% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBANRXRX
| Q1 26 | $39.9M | — | ||
| Q4 25 | $36.9M | $35.5M | ||
| Q3 25 | $32.8M | $5.2M | ||
| Q2 25 | $32.5M | $19.2M | ||
| Q1 25 | $30.0M | $14.7M | ||
| Q4 24 | $30.8M | $4.5M | ||
| Q3 24 | $28.6M | $26.1M | ||
| Q2 24 | $27.9M | $14.4M |
净利润CBANRXRX
| Q1 26 | $8.2M | — | ||
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $5.8M | $-162.3M | ||
| Q2 25 | $8.0M | $-171.9M | ||
| Q1 25 | $6.6M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $5.6M | $-95.8M | ||
| Q2 24 | $5.5M | $-97.5M |
毛利率CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | 25.9% | -304.8% | ||
| Q3 25 | 22.2% | -3327.6% | ||
| Q2 25 | 30.9% | -916.8% | ||
| Q1 25 | 27.6% | -1297.9% | ||
| Q4 24 | 28.8% | -4042.4% | ||
| Q3 24 | 24.6% | -377.1% | ||
| Q2 24 | 24.8% | -697.4% |
净利率CBANRXRX
| Q1 26 | 20.6% | — | ||
| Q4 25 | — | -304.2% | ||
| Q3 25 | 17.7% | -3135.3% | ||
| Q2 25 | 24.6% | -894.2% | ||
| Q1 25 | 22.0% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 19.7% | -367.5% | ||
| Q2 24 | 19.6% | -676.6% |
每股收益（稀释后）CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | $0.42 | $-0.17 | ||
| Q3 25 | $0.33 | $-0.36 | ||
| Q2 25 | $0.46 | $-0.41 | ||
| Q1 25 | $0.38 | $-0.50 | ||
| Q4 24 | $0.43 | $-0.56 | ||
| Q3 24 | $0.32 | $-0.34 | ||
| Q2 24 | $0.31 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $295.8M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $380.4M | $1.1B |
| 总资产 | $3.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CBANRXRX
| Q1 26 | $295.8M | — | ||
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M |
总债务CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | $258.1M | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $248.0M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
股东权益CBANRXRX
| Q1 26 | $380.4M | — | ||
| Q4 25 | $375.9M | $1.1B | ||
| Q3 25 | $302.3M | $1.0B | ||
| Q2 25 | $293.9M | $919.1M | ||
| Q1 25 | $286.9M | $933.9M | ||
| Q4 24 | $278.7M | $1.0B | ||
| Q3 24 | $276.1M | $524.6M | ||
| Q2 24 | $264.7M | $584.4M |
总资产CBANRXRX
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.7B | $1.5B | ||
| Q3 25 | $3.2B | $1.4B | ||
| Q2 25 | $3.1B | $1.3B | ||
| Q1 25 | $3.2B | $1.3B | ||
| Q4 24 | $3.1B | $1.4B | ||
| Q3 24 | $3.1B | $726.5M | ||
| Q2 24 | $3.0B | $775.9M |
负债/权益比CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | 0.69× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.89× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | $-5.5M | $-46.1M | ||
| Q3 25 | $14.4M | $-117.4M | ||
| Q2 25 | $15.8M | $-76.4M | ||
| Q1 25 | $17.9M | $-132.0M | ||
| Q4 24 | $23.4M | $-115.4M | ||
| Q3 24 | $20.5M | $-59.2M | ||
| Q2 24 | $1.1M | $-82.2M |
自由现金流CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | $-6.9M | $-47.3M | ||
| Q3 25 | $14.1M | $-117.6M | ||
| Q2 25 | $15.8M | $-79.6M | ||
| Q1 25 | $17.6M | $-133.8M | ||
| Q4 24 | $22.3M | $-116.7M | ||
| Q3 24 | $20.2M | $-63.8M | ||
| Q2 24 | $990.0K | $-83.4M |
自由现金流率CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | -18.7% | -133.1% | ||
| Q3 25 | 42.9% | -2272.5% | ||
| Q2 25 | 48.5% | -413.9% | ||
| Q1 25 | 58.7% | -907.4% | ||
| Q4 24 | 72.5% | -2567.7% | ||
| Q3 24 | 70.6% | -244.6% | ||
| Q2 24 | 3.5% | -578.5% |
资本支出强度CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | 3.5% | ||
| Q3 25 | 1.1% | 4.7% | ||
| Q2 25 | 0.3% | 16.4% | ||
| Q1 25 | 1.2% | 12.4% | ||
| Q4 24 | 3.5% | 28.6% | ||
| Q3 24 | 1.0% | 17.5% | ||
| Q2 24 | 0.5% | 8.2% |
现金转化率CBANRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.48× | — | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 2.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.64× | — | ||
| Q2 24 | 0.20× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBAN
| Net Interest Income | $29.2M | 73% |
| Noninterest Income | $10.7M | 27% |
RXRX
暂无分部数据
